Airoldi M, Fazio M, Gandolfo S, Vercellino V, Ozzello F, Pedani F, Camoletto D, Negri L
Cancer. 1985 Aug 1;56(3):424-31. doi: 10.1002/1097-0142(19850801)56:3<424::aid-cncr2820560303>3.0.co;2-v.
Eighty-four previously untreated patients (69 males, 15 females) with squamous carcinoma of the tongue (30 patients), floor of the mouth (30), cheek (16), and retromolar region (8) were treated using a protocol comprising cryosurgery + chemotherapy, followed by external 60Co radiotherapy. The follow-up period was at least 6 months (median, 50 months). Cryosurgery (1-2 sessions in 49 T1-2 cases; 2-4 in 35 T3-4 cases) was accompanied by a CMF (cyclophosphamide, methotrexate, 5-fluorouracil) schedule (T1-2, two courses; T3-4, three courses). Radiotherapy was given 15 to 20 days after combined cryochemotherapy (T1, 50 Gy on tumor and lymph nodes; T2-3-4, same with an extra dose of 10 to 15 Gy on the primary lesion). Complete remission was reached 4 months after treatment in 76 of 84 patients (90.5%). Survival with no evidence of disease (NED) in the 57 patients (27 T1-2, 30 T3-4) with a follow-up of more than 3 years was 59.6% for the series as a whole, 70.3% for T1-2, and 50.0% for T3-4; 78.2% for the tongue, 52.6% for the floor, 66.6% for the cheek, and 0% for the retromolar region. The picture was much the same after 5 years. Actuarial survival at 6 years was 66% in the series as a whole, 75.5% in T1-2, and 57.5% in T3-4 (tongue 86.9%, floor 56.1%, cheek 68.4%, and retromolar region 0%). It is believed that the results obtained in tumors of the tongue, floor and cheek, coupled with the conservative aspects of the protocol, make it a suitable subject for a controlled trial.
84例既往未接受过治疗的舌（30例）、口底（30例）、颊部（16例）和磨牙后区（8例）鳞状细胞癌患者（69例男性，15例女性），采用冷冻手术+化疗方案治疗，随后进行60Co外照射放疗。随访期至少6个月（中位数为50个月）。冷冻手术（49例T1-2期患者进行1-2个疗程；35例T3-4期患者进行2-4个疗程）同时采用CMF（环磷酰胺、甲氨蝶呤、5-氟尿嘧啶）方案（T1-2期，两个疗程；T3-4期，三个疗程）。在冷冻化疗联合治疗后15至20天给予放疗（T1期，肿瘤和淋巴结给予50 Gy；T2-3-4期，同样剂量，原发灶额外增加10至15 Gy）。84例患者中有76例（90.5%）在治疗后4个月达到完全缓解。57例随访超过3年的患者（27例T1-2期，30例T3-4期）无疾病证据（NED）的生存率，整个系列为59.6%，T1-2期为70.3%，T3-4期为50.0%；舌部为78.2%，口底为52.6%，颊部为66.6%，磨牙后区为0%。5年后情况大致相同。整个系列6年的精算生存率为66%，T1-2期为75.5%，T3-4期为57.5%（舌部86.9%，口底56.1%，颊部68.4%，磨牙后区0%）。据信，在舌、口底和颊部肿瘤中获得的结果，以及该方案的保守性，使其成为适合进行对照试验的对象。
